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Abstract
Background: Severe asthma (SA) may require frequent courses or chronic use of oral corticosteroids (OCS),
inducing many known side effects and complications. Therefore, it is important to identify risk factors of chronic
use of OCS in SA, considering the heterogeneity of clinical and inflammatory asthma phenotypes. Another aim of
the present analysis is to characterize a subpopulation of severe asthmatics, in whom blood eosinophil counts (BEC)
remain elevated despite chronic OCS treatment.
Methods: In a cross-sectional analysis of 982 SA patients enrolled in the Belgian Severe Asthma Registry (BSAR)
between March 2009 and February 2019, we investigated the characteristics of the OCS treated patients with
special attention to their inflammatory profile.
Results: At enrollment, 211 (21%) SA patients were taking maintenance OCS (median dose: 8 [IQR: 5–10]) mg
prednisone equivalent). BEC was high (> 400/mm3) in 44% of the OCS treated population. Multivariable logistic
regression analysis showed that risk factors for chronic use of OCS in SA were late-onset asthma (i.e. age of onset >
40 yr), frequent exacerbations (i.e. ≥2 exacerbations in the previous year) and non-atopic asthma. Late-onset asthma
was also a predictor for persistently high BEC in OCS treated SA patients.
Conclusion: These data showed a significant association between a persistently high BEC and late-onset asthma in
OCS treated SA patients. Whether it is poor compliance to treatment or corticosteroid insensitivity the reasons for
this association warrants further investigation.
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Although severe asthma (SA) represents only 5–10% of
the population with asthma [1], the condition accounts
for a major part of the financial burden to health care
systems posed by asthma [2]. More than half of the
incremental cost has been recently attributed to comor-
bidities [3].
SA defined according to a joint statement from the
European Respiratory Society and the American
Thoracic Society (ERS/ATS) may require frequent or
chronic use of oral corticosteroids (OCS). Indeed, OCS
are prescribed as maintenance therapy in 45% of adult
SA patients who remain uncontrolled despite GINA step
4–5 treatment [4].
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However, OCS are responsible for serious side effects
[5] and complications accounting for a significant eco-
nomic burden [6, 7].
OCS effectively target elements of the T2 inflamma-
tory pathway, suppressing blood eosinophils quite rap-
idly [8] and decreasing mast cells in airway smooth
muscle [9]. Yet some patients still present with high
blood eosinophil levels (≥ 400/mm3) despite OCS main-
tenance therapy.
The goals of the present analysis were to compare pa-
tients with and without OCS maintenance, and to
characterize patients with high levels of blood eosino-
phils despite this treatment. For this purpose, we used
the Belgian Severe Asthma Registry (BSAR), which is a
cohort of adult severe asthmatics and aims at enhancing
awareness and knowledge on the natural history of SA
in order to optimize patient care [10].
Methods
In a cross-sectional analysis on SA patients enrolled in
the BSAR, we compared characteristics of SA patients
chronically using OCS with those SA patients who did
not. Chronic OCS use was defined as daily use of OCS.
Furthermore, we made a comparison of patients with
high (≥400/mm3) and low blood eosinophil counts
(BEC) under OCS.
We also looked at a small number of severe asthmatics
with persistently elevated BEC despite OCS therapy in
whom an anti-IL5 monoclonal antibody was started.
Between March 2009 and February 2019, severe asth-
matics [1] from 21 Belgian centers were enrolled in the
BSAR, utilizing a secured web database which admits
password protected anonymized data [10], after gaining
fully informed written consent (2008/221). The Ameri-
can Thoracic Society definition of SA [11] was used for
patients recruited between 2009 and 2014. As the defin-
ition of SA changed in 2014 [1], the BSAR website was
adapted accordingly.
Asthma was diagnosed based on symptoms of cough,
breathlessness or dyspnea together with the demonstra-
tion of airflow variability [12]. The latter was defined by
one or more of the following: increase in forced expira-
tory volume in 1 s (FEV1) of 12% or greater after
inhalation of 400 μg of salbutamol or an inhaled concen-
tration of methacholine provoking a 20% fall in FEV1 of
less than 16mg/ml. Methacholine challenges were per-
formed according to a standardized methodology as pre-
viously described [13].
Other prerequisites for inclusion were: age ≥ 18 years,
asthma follow-up by a respiratory physician for at least
12 months, education on the disease provided to the pa-
tient, and compliance thought to be satisfactory in order
to include only patients with severe refractory asthma
and those in whom comorbidities had been addressed.
All the data presented were collected at the time point
of recruitment into the registry.
Patients were characterized as atopic if they had at
least one positive specific IgE (> 0.35 kU/l; ImmunoCAP
system, Phadia AB, Uppsala; Sweden) to at least one
common aeroallergen (cat, dog, house dust mites, grass
pollen, tree pollen and a mixture of molds) or a positive
skin prick test. An exacerbation in the previous year was
defined by a course of OCS for at least 3 days for asthma
worsening. Emergency room visits, hospitalizations, and
intensive care unit stays were also recorded. Presence
(or absence) of treatment with long-acting muscarinic
antagonists (LAMA), short or long-acting ß2-agonists
(SABA, LABA), anti-IgE, anti-IL5 and macrolides was
recorded, as well as OCS maintenance doses.
Quality of life was assessed using the self-administered
Asthma Quality of Life Questionnaire (AQLQ) [14] and
asthma control by both the Juniper Asthma Control
Questionnaire (ACQ) [15] and the Asthma Control Test
(ACT) [16].
Patients underwent FENO measurement at a flow rate
of 50 ml/s according to the ERS/ATS recommendations
(NIOX, Aerocrine, Sweden) [17] followed by spirometry
with bronchodilation (inhalation of 400 μg salbutamol)
and complete pulmonary function tests with evaluation
of lung volumes and diffusion capacity.
Tobacco status were recorded. An ex-smoker was de-
fined as someone who had stopped smoking for at least
6 months.
Sputum was induced almost exclusively in Liège and
processed as previously reported [18]; 225 sputum sam-
ples were collected in the data set (23% of the total
population). Cell counts were estimated on samples cen-
trifuged (Cytospin) and stained with Hemacolor® Stain-
ing set after counting 500 non-squamous cells (Merck
chemical, Overijste, Belgium). Sputum cytology was ana-
lyzed and 4 phenotypes were defined: the eosinophilic
phenotype with ≥3% sputum eosinophil count (and <
76% neutrophil count), the neutrophilic phenotype with
≥76% sputum neutrophil count (and < 3% eosinophil
count), and the mixed granulocytic phenotype being a
combination of the above [19]. The fourth was paucigra-
nulocytic phenotype, defined as an inflammatory cell
count below these thresholds. Blood samples were
drawn for evaluation of total serum IgE levels, specific
IgE and BEC.
Nasal polyps and sinusitis were diagnosed by Ear Nose
and Throat specialists either by endoscopy or sinus CT
scanner. Gastroesophageal reflux was diagnosed either
upon anamnesis (symptoms of heartburn), or by the
presence of oesophagitis upon gastroscopy or treatment
response to PPI. Chest CT imaging was obtained in pa-
tients with an atypical presentation of SA and in case of
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history of smoking. Hospital Anxiety and Depression
Scale (HADS) questionnaires [20] were used to assess
psychopathology.
Data on vocal cord dysfunction, allergic bronchopul-
monary aspergillosis, Aspirin-sensitivity, eosinophilic
granulomatosis with polyangiitis (EGPA: formerly called
Churg-Strauss syndrome), occupational asthma (asthma
acquired in the workplace), premenstrual asthma, and
obesity were also collected.
Near-fatal asthma is described as an asthma attack that
require intensive care unit stay with mechanical ventilation.
BEC were categorized in 4 groups: < 150/mm3, between
150 and 299/mm3, between 300 and 400/mm3, and > 400/
mm3 to evaluate eosinophil levels in patients treated with
OCS and the mean dose of OCS in each group.
Finally, an analysis was conducted to compare patients
normalizing their BEC (< 400/mm3) under OCS treat-
ment versus those who did not.
Statistical methods
Continuous variables are presented as mean and SD
when normally distributed or as median and interquar-
tile range (IQR) when not normally distributed. Categor-
ical variables were presented as frequencies and
percentages. Continuous variables were compared by t-
test when normally distributed or by Wilcoxon Mann-
Whitney test when non-parametric. ANOVA or Kruskal
Wallis analyses were conducted in order to compare
more than 2 groups (categories). Fisher exact test was
used to compare qualitative variables.
Predicting factors of “chronic OCS use” were assessed by
a logistic regression using independent variables such as
atopy, gender, age, body mass index, age of asthma onset,
smoking status, pack-year, and measurements of ACQ,
FENO, post-bronchodilation FEV1%, sputum % eosinophils
and neutrophils, BEC, presence of exacerbations, and hospi-
talizations during the last year and comorbidities such as
nasal polyps, rhinosinusitis, bronchiectasis, emphysema,
obesity, GERD, allergic bronchopulmonary aspergillosis,
vocal cord dysfunction, aspirin-sensitivity, EGPA, psychop-
athy, occupational, premenstrual, or Aspergillar asthma.
Chronic OCS use was used as the dependent variable. After
examining for all potential predictors, the univariate associ-
ation with the outcome, a stepwise backward logistic re-
gression was conducted; initial model included variables
with an association of p < 0.20. Then, the best predictive
model was conducted deleting those variables that had the
weakest association with the outcome (p > 0.05). This ana-
lysis (logistic regression) was repeated in order to identify
predictors of BEC ≥ 400mm3.
A p value < 0.05 was considered statistically significant.
Statistical analysis was done using STATA version 14.0
(Statistical Software, College Station, TX: StataCorp LP).
Results
Between March 2009 and February 2019, 982 severe
asthmatics that fulfilled the definition of SA [1, 11] were
enrolled in the BSAR.
Characteristics of OCS maintenance treated SA patients
Demographic, functional and inflammatory characteris-
tics and comorbidities of SA patients are shown in
Table 1. At enrollment in the BSAR, 211 (21%) SA pa-
tients were taking maintenance OCS (median dose
(IQR): 8 (5–10) mg prednisone equivalent/day). The
proportion of males was higher (p = 0.02) in SA patients
treated with maintenance OCS and these patients sig-
nificantly more often had late-onset (≥40 yr) asthma
(p < 0.0001), were less atopic (p < 0.0001), and presented
with higher FENO (p = 0.03) and higher exacerbation
rates (p < 0.0001) compared to OCS naïve SA patients.
OCS-treated SA patients also had worse asthma control
(p = 0.03) and asthma-related quality of life scores (p =
0.03). Moreover, comorbidities such as emphysema (p =
0.002), bronchiectasis (p = 0.001), GERD (p = 0.007) and
EGPA (p < 0.0001) were more prevalent in the chronic
OCS-treated SA group.
Interestingly, BEC were similar (p = 0.2) between
OCS-treated and not treated SA patients with 44% pa-
tients with high BEC (> 400/mm3) in the OCS-treated
group (Fig. 1). Even in SA patients treated with the high-
est dose of OCS (> 16mg/d of prednisone equivalent),
27% still had high BEC.
When selecting only patients on biologics (anti-IL5
or anti-IgE) (n = 270) (Table S1), the proportion of
males was higher (p = 0.001) in SA patients treated
with maintenance OCS and these patients were less
atopic (p = 0.005), and presented with higher exacer-
bation rates (p = 0.0009) compared to OCS naïve SA
patients. OCS-treated SA patients also had worse
asthma control (p = 0.03). Moreover, sputum eosino-
phils were lower (p = 0.02) and sputum neutrophils
higher (p = 0.005) in the OCS treated patients.
Predictors of OCS maintenance use
The results of the univariate logistic regression analysis
showed an increased risk of using maintenance OCS in
non-atopic male and between 44- and 64-years old SA
patients with late-onset asthma (i.e. age of onset ≥40 yr),
frequent exacerbations (i.e. ≥ 2 exacerbations in last 12
months), GERD and EGPA.
Multivariable logistic regression analysis (Table 2)
showed that late-onset asthma (OR [95%CI]:1.98 [1.27–
3.08], p = 0.003), frequent exacerbations (OR [95%CI]:
3.73 [2.41–5.77], p < 0.0001) and non-atopic status (0.59
[0.42–0.84], p = 0.003) were predictive of chronic use of
OCS in SA.
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Table 1 Comparison of SA patients with or without chronic OCS treatment (n = 982)
Characteristics No chronic OCS use Chronic OCS use P-value
N (%) 771 (79) 211 (21) N/A
Gender: F (%) (n = 982) 463 (60) 107 (51) 0.018
Age (n = 981) 53 ± 16 55 ± 17 0.0792
Age of onset (%) (n = 982)
< 12 yr 241 (32) 41 (20) < 0.0001
12–40 yr 296 (39) 71 (34)
≥ 40 yr 222 (29) 97 (46)
BMI (n = 982) 28 ± 13 27 ± 5 0.2454
Smoking History: (n = 982)
Never (%) 471 (61) 126 (60) 0.092
Current (%) 62 (8) 9 (4)
Ex (%) 238 (31) 76 (36)
Estimated number of packyears (n = 386) 15 (7–25) 15 (7–25) 0.7406
Atopic status: y (%) (n = 982) 554 (72) 119 (56) < 0.0001
Respiratory Familial History of asthma: true (%) (n = 982) 348 (45) 70 (33) 0.001
Current housing: (n = 975)
City (%) 241 (31) 57 (28) 0.201
Countryside (%) 281 (37) 70 (34)
Sub-urban (%) 246 (32) 80 (39)
SABA: y (%) (n = 982) 656 (85) 176 (83) 0.3080
LABA: y (%) (n = 982) 755 (98) 211 (100) 0.4520
LAMA: y (%) (n = 982) 20 (3) 8 (4) 0.2380
OCS dose (median IQR) (%)
< 4 N/A 29 (14) N/A
4–8 76 (36)
8–16 72 (34)
> 16 mg/d 34 (16)
Anti-IL5: y (%) (n = 982) 63 (8) 36 (17) < 0.0001
Anti-IgE: y (%) (n = 982) 140 (18) 31 (15) 0.1410
Macrolides: y (%) (n = 982) 4 (1) 1 (1) 0.7070
ACT (n = 758) 14.0 ± 5.3 12.9 ± 5.2 0.0195
ACQ (n = 642) 2.5 ± 1.3 2.8 ± 1.4 0.0319
AQLQ (n = 686) 4.2 ± 1.4 3.9 ± 1.4 0.0259
Exacerbations in last 12 months (n = 966) 2 (0–3) 3 (1–4) < 0.0001
≥3 OCS burst for asthma exacerbation in last 12 months (n = 966) 235 (31) 128 (60) < 0.0001
Number of emergency visits in last year (n = 340) 1 (0–1) 1 (0–2) 0.1177
Number of hospitalizations in last year (n = 337) 1 (0–1) 1 (0–1) 0.0690
Near fatal episodes last year (n = 99) 0 (0–0) 0 (0–1) 0.2762
Death: (%) (n = 982) 5 (0.6) 5 (2.4) 0.043
FEV1 (L) (n = 953) 2.01 ± 0.81 1.97 ± 0.86 0.5144
FEV1 (% predicted) (n = 953) 69 ± 21 67 ± 23 0.1874
FVC (% predicted) (n = 953) 87 ± 19 87 ± 23 0.7476
FEV1/FVC (% predicted) (n = 953) 64 ± 12 62 ± 13 0.0508
FEV1 Reversibility (n = 793) 11 ± 14 12 ± 13 0.1299
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Characteristics of eosinophilic (BEC ≥400/mm3) SA
patients treated with maintenance OCS
In the population of OCS treated patients, a comparison
was made between patients with BEC ≥400 and < 400
mm3.
Demographic, functional and inflammatory character-
istics and comorbidities of the 79 OCS-treated SA pa-
tients with high BEC (≥400/mm3) were compared to
those with low BEC in Table 3. Despite similar OCS
doses, eosinophilic patients significantly more often had
Table 1 Comparison of SA patients with or without chronic OCS treatment (n = 982) (Continued)
Characteristics No chronic OCS use Chronic OCS use P-value
Total Lung Capacity (n = 838) 103 (91–115) 102 (89–113) 0.3674
Functional Residual Capacity (n = 692) 115 (96–141) 117 (98–138) 0.9700
Residual Volume (n = 782) 137 (110–167) 136 (107–171) 0.4914
DLCO (%) (n = 700) 83 ± 21 80 ± 19 0.1038
KCO (%) (n = 672) 98 ± 21 97 ± 20 0.6176
PC20M Value (mg/ml) (n = 88) 1.1 (0.26–8.00) 0.34 (0.10–2.00) 0.1338
Total serum IgE (kU/l) (n = 818) 182 (66–506) 162 (66–366) 0.3237
Blood Eosinophils (/mm3) (n = 800) 290 (120–526) 339 (110–685) 0.2006
Blood Eosinophils (/mm3) (n = 800)
< 150 192 (30) 52 (31) 0.071
150–300 133 (21) 22 (13)
300–400 81 (13) 21 (12)
> 400 225 (36) 74 (44)
Sputum eosinophils (%) (n = 225) 7.2 (1.4–37.0) 6.0 (0.4–21.0) 0.1753
Sputum neutrophils (%) (n = 225) 51 (29–73) 63 (35–80) 0.3453
Sputum inflammatory (n = 225)
Phenotypes:
Paucigranulo 18% 19% 0.450
Eosino (≥3%) 60% 49%
Neutro (≥76%) 17% 26%
Mixed 5% 7%
Exhaled NO (50 ml/sec) (ppb) (n = 689) 24 (13–47) 30 (17–58) 0.0269
Emphysema (n = 971) 65 (9) 23 (11) 0.002
Bronchiectasis (n = 971) 109 (14) 42 (20) 0.001
Rhinosinusitis (n = 971) 396 (52) 118 (56) 0.463
Nasal polyposis (n = 971) 193 (26) 66 (31) 0.178
Overweight or obesity (n = 971) 393 (52) 100 (48) 0.507
Psychopathology (n = 971) 140 (18) 39 (19) 0.630
GERD (n = 971) 262 (34) 94 (45) 0.007
Vocal Cord Dysfunctions (n = 292) 1 (0.5) 1 (1) 0.371
ABPA (n = 971) 31 (4) 11 (5) 0.679
Aspirine-sensitive asthma (n = 971) 46 (6) 18 (9) 0.323
EGPA (Churg Strauss) (n = 971) 13 (2) 14 (7) < 0.0001
Occupational asthma (n = 971) 24 (3) 7 (3) 0.1950
Premenstrual asthma (n = 971) 6 (1) 1 (0.5) 0.936
Aspergillar asthma (n = 292) 7 (3) 4 (6) 0.312
Data are presented as mean ± SD or median and IQR. BMI Body Mass Index, SABA short acting beta-2 agonists, LABA long acting beta-2 agonists, LAMA long acting
muscarinic antagonists, OCS oral corticosteroids, FEV1 forced expiratory volume in 1 , FVC forced vital capacity, TLC total lung capacity, FRC functional residual
capacity, RV residual volume, DLCO diffusing capacity of lung for carbon monoxide, KCO transfer coefficient of the lung for carbon monoxide, PC20M provocative
concentration of metacholine causing a 20% fall in FEV1 ppb, parts per billion, NO nitric oxide, ppb, parts per billion, ACT Asthma Control Test, ACQ Asthma
Control Questionnaire, AQLQ Asthma Quality of Life Questionnaire, GERD gastroesophageal reflux disease, ABPA allergic bronchopulmonary aspergillosis, EGPA
Eosinophilic granulomatosis with polyangiitis, N/A not applicable
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late-onset asthma (p < 0.0001) (Fig. 2), higher levels of
FENO (p = 0.0005), as well as higher eosinophil (p =
0.02) and lower neutrophil (p = 0.0004) counts in their
sputum than the SA group with a low BEC. These eo-
sinophilic patients also had a higher prevalence of nasal
polyposis (p = 0.04) and a lower prevalence of anxiety
and depression (p = 0.004). Moreover, patients with low
BEC had slightly poorer lung function (lower FEV1 (p =
0.04) and FVC% (p = 0.009) but similar FEV1/FVC and
also poorer asthma control (p = 0.04) than the group
with a high BEC. These patients also had a higher preva-
lence of emphysema (p = 0.02).
Predictors of high BEC (≥400/mm3) in OCS treated SA
patients
The results of the univariate logistic regression analysis
showed an increased risk of being eosinophilic despite
maintenance OCS in patients with late-onset asthma,
high FEV1%, high FENO (> 50 ppb), and increased spu-
tum eosinophils (> 21%), but decreased risk are seen in
patients with higher sputum neutrophils. Multivariable
logistic regression analysis (Table 4) showed that late-
onset asthma (OR (IC95%): 31.6 (3.6–276.9), p = 0.0047)
was a predictor for persistently high BEC in OCS-treated
SA patients. However, a high ACQ score (> 3.9) was in-
versely associated with high BEC (OR (IC95%): 0.17
(0.05–0.63), p = 0.0458). Indeed, compared to patients
with ACQ scores lower than 3.9 (75th percentile), pa-
tients with an ACQ score higher than 3.9 (n = 31) were
characterized by low BEC, impaired lung function (low
FEV1) and diffusing capacity of lung for carbon monox-
ide (DLCO), and a higher rate of emphysema (52%) sug-
gestive of Asthma COPD overlap.
BEC before and after anti-IL5 treatment initiation
In a sub-analysis, 12 patients treated with OCS and per-
sistently elevated BEC (≥400/mm3) (594 (535–821)/
mm3), were started on an anti-IL5 monoclonal antibody
after enrolment in BSAR. We observed normalization
(BEC < 400/mm3) of BEC (62 (39–91)/mm3) in all these
patients after one year of anti-IL5 therapy. Also, as pre-
viously shown, the OCS dose was significantly reduced
from 8 (7–10) to 4 (2–7) mg daily (p = 0.0065) after
addition of the biologic therapy.
Discussion
In this study, we found that approximately one-fifth of
SA patients included in BSAR was treated with mainten-
ance OCS and that a high proportion (44%) of these pa-
tients still showed a high BEC. The data indicated that
late-onset asthma, frequent exacerbations and non-
atopic status are associated with OCS maintenance use
in SA. Late-onset asthma was also a predictor for per-
sistently high BEC despite OCS.
At enrollment in the registry, 21% of SA patients were
taking maintenance OCS, which is a lower proportion of
severe asthmatic than previously described by Chung
Fig. 1 Blood eosinophil count in SA: Proportions of BEC in severe asthmatics according to (presence or absence of) chronic OCS treatment. BEC
categories: < 150; ≥150- < 300; ≥300- < 400; ≥400 (/mm3)
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[1]. A partial explanation for this discrepancy could be
that in about 26% of this subpopulation, a biotherapy
(either IL-5 inhibitors or anti-IgE) had already been
started prior to enrolment in BSAR. Indeed, OCS-
sparing effects have been reported to be close to 50%
with these biotherapies [21–23].
Our data confirms the predominance of females in the
overall SA population [10]. However, we found a higher
proportion of males in severe asthmatics using mainten-
ance OCS when compared to non-OCS treated patients.
A higher proportion of males was previously reported in
eosinophilic asthma [24, 25] and eosinophilic asthma has
Table 2 Factors associated with maintenance OCS use. Results of the logistic regression – Multivariable analysis – Backward
stepwise predictive model (p < 0.2)
Chronic OCS use Total population (n = 953)
UNIVARIATE MULTIVARIATE
OR 95%CI P-value OR 95%CI P-value
Atopy 0.51 0.37–0.69 < 0.0001 0.59 0.42–0.84 0.0030
Age of onset
(< 12) < 0.0001 0.0034
≥ 12; < 40 1.41 0.93–2.15 1.20 0.77–1.86
≥ 40 2.57 1.71–3.86 1.98 1.27–3.08
Exacerbations in last 12 months
(< 0) < 0.0001 < 0.0001
≥ 0; < 2 1.16 0.73–1.87 1.16 0.72–1.89
≥ 2 3.73 2.44–5.70 3.73 2.41–5.77
Female 0.68 0.50–0.93 0.015 NS
Smoking (Never)
Current 0.54 0.26–1.12 0.1020 NS
Ex 1.19 0.86–1.65
Age (< 44)
≥ 44; < 55 1.70 1.09–2.65 0.0385 NS
≥ 55; < 64 1.86 1.18–2.91
≥ 64 1.41 0.89–2.23
Number of hospitalizations in last year (< 0)
≥ 0; < 1 1.10 0.65–1.85 0.0976 NS
≥ 1 2.01 1.04–3.87
FEV1% (< 53)
≥ 53; < 68 0.70 0.46–1.07 0.1845 NS
≥ 68; < 83 0.64 0.41–0.96
≥ 83 0.75 0.49–1.16
Exhaled NO (50 ml/sec) (ppb) 1.0049 1.00053–1.00948 0.028 NS
Blood eosinophils (/mm3) (< 150)
≥ 150; < 300 0.61 0.35–1.05 0.0815 NS
≥ 300; < 400 0.95 0.54–1.69
≥ 400 1.21 0.81–1.81
Nasal polyps 1.37 0.98–1.93 0.067 NS
GERD 1.59 1.16–2.17 0.004 NS
ABPA 1.29 0.64–2.62 0.477 NS
Aspirin sensitive 1.47 0.83–2.60 0.183 NS
EGPA (Churg-Strauss) 4.21 1.94–9.11 0.000 NS
OR odds ratio, CI confidence interval, FEV1 forced expiratory volume in 1 s, NO nitric oxide, ppb parts per billion, GERD gastroesophageal reflux disease, ABPA
allergic bronchopulmonary aspergillosis, EGPA Eosinophilic granulomatosis with polyangiitis, NS not significant
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been shown to respond well to chronic inhaled cortico-
steroids and OCS treatment [26–28].
There are different phenotypes of SA. Among these
phenotypes, late-onset non allergic asthma has been
found to occur after the age of 40, to be frequently asso-
ciated with nasal polyps and chronic rhinosinusitis, and
to be prone to exacerbations with good response to OCS
[25]. In our study, not surprisingly, chronic use of OCS
was predicted by late-onset of asthma (≥40 yr), high (≥ 2)
exacerbation rates in the previous year, and non-atopic
status. Late-onset asthma was also a predictor for high
BEC (> 400/mm3) in OCS maintenance treated severe
Table 3 Comparison of OCS maintenance SA patients with BEC < 400 or BEC ≥ 400 (n = 174)
Characteristics BEC < 400 BEC ≥400 P-value
N (%) 95 (55) 79 (45) N/A
Age of onset (%) (yr) (n = 173)
< 12 25 (27) 6 (8) 0.000
12–40 37 (39) 26 (33)
> 40 32 (34) 47 (59)
ACQ (n = 61) 2.97 ± 1.29 2.40 ± 1.37 0.0367
FEV1 (% predicted) (n = 110) 63.7 ± 23.6 71.7 ± 22.4 0.0267
FVC (% predicted) (n = 110) 83 ± 21 93 ± 23 0.0088
Sputum eosinophils (%) (n = 38) 2.8 (0.4–10.0) 46.5 (4.7–66.8) 0.0223
Sputum neutrophils (%) (n = 38) 70.0 (54.0–80.0) 21.7 (9.5–40.5) 0.0004
Exhaled NO (50 ml/sec) (ppb) (n = 67) 23 (13–42) 38 (19–83) 0.0005
Emphysema (based on Chest CT Scanner) (n = 174) 15 (16) 7 (9) 0.025
Nasal polyposis (n = 174) 25 (26) 33 (42) 0.042
Psychopathology (n = 174) 25 (26) 9 (11) 0.004
Data are presented as mean ± SD or median and IQR. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ppb parts per billion, NO nitric oxide, ppb
parts per billion, ACQ Asthma Control Questionnaire, N/A not applicable
Fig. 2 Late-onset asthma predominance and eosinophilia: Distribution of age onset in severe asthmatic with chronic OCS use according to BEC.
Age of asthma onset categories: < 12; ≥12- < 40; ≥40 (yr)
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asthmatics. Poor response of eosinophils to OCS in this
subpopulation needs to be further investigated.
Although OCS are known to suppress eosinophils, BEC
were not different between SA patients using maintenance
OCS and the ones that do not. We also noticed a high
prevalence of patients with high BEC (> 400/mm3) in the
OCS maintenance treated SA patients. In these patients
with high BEC despite OCS maintenance, we may now
offer anti-IL5 therapy to decrease the risk of exacerbation
[29–31]. Persistently high peripheral blood eosinophils
have been previously reported in OCS treated asthmatics
[22, 32–34]. MENSA, DREAM and SIRIUS studies show
high BEC (MENSA: 320 ± 938 to 280 ± 987); DREAM:
280 ± 1010 to 230 ± 1200; SIRIUS: 250 ± 1245 to 230 ±
1001) despite variable prevalence (25, 30 and 100%, re-
spectively) of patients on OCS maintenance therapy.
Whether poor compliance or adherence [35] to treatment
or corticosteroid insensitivity are the reasons for high BEC
despite OCS maintenance therapy remains unclear.
The lack of measure of compliance/ adherence to
treatment represents the first limitation of our study.
Poor adherence to treatment is seen in about 32–56% of
severe asthmatics [1]. Although compliance was not ob-
jectively measured in these severe asthmatic patients, the
BSAR investigators only enrolled their patients in the
registry if they considered compliance to have been sat-
isfactory in the previous 12 months. We also cannot be
absolutely sure that the reported BEC have been mea-
sured while patients were actually taking OCS. Indeed,
some investigators of BSAR could have provided histor-
ical BEC (before starting chronic OCS) or could have
stopped OCS in order to obtain a blood eosinophils level >
300/mm3, required for the reimbursement of anti-IL5 in
Belgium. Nevertheless, at least the major contributing
Table 4 Factors associated with BEC≥ 400. Results of the logistic regression – Multivariable analysis - Backward stepwise predictive
model (p < 0.2)
BEC≥ 400 Total population (n = 174)
UNIVARIATE MULTIVARIATE
OR 95%CI P-value OR 95%CI P-value
Age onset (< 12)
≥ 12; < 40 2.93 1.05–8.13 0.0009 13.6 1.6–116.8 0.0047
≥ 40 6.12 2.26–16.60 31.6 3.6–276.9
ACQ (< 1.6)
≥ 1.6; < 2.9 0.36 0.12–1.11 0.0926 0.29 0.08–1.00 0.0458
≥ 2.9; < 3.9 0.46 0.15–1.39 0.58 0.16–2.08
≥ 3.9 0.23 0.07–0.76 0.17 0.05–0.63
Atopy 0.66 0.35–1.20 0.176 NS
Smoking (Never)
Current 0.53 0.12–2.35 0.0608 NS
Ex 0.46 0.24–0.88
Age (< 48)
≥ 48; < 56 1.58 0.66–3.75 0.1448 NS
≥ 56; < 64 0.80 0.34–1.87
≥ 64 1.97 0.85–4.59
FEV1% 1.02 1.00–1.03 0.029 NS
Exhaled NO (ppb) (< 25)
≥ 25; < 50 1.83 0.76–4.45 0.0073 NS
≥ 50 4.13 1.70–10.00
Sputum Eosinophils % (< 0.4)
≥ 0.4; < 3.0 1.29 0.07–24.39 0.0437 NS
≥ 3.0; < 21.0 0.82 0.04–15.00
≥ 21.0 15 1.21–185.20
Sputum Neutrophils % 0.94 0.90–0.98 0.003 NS
Nasal polyposis 1.84 0.96–3.53 0.066 NS
OR odds ratio, CI confidence interval, ACQ Asthma Control Questionnaire, FEV1 forced expiratory volume in 1 s, NO nitric oxide, ppb parts per billion. NS
not significant
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centers have confirmed that patients were already on OCS
maintenance therapy at the time of blood sample collec-
tion. Another limitation of our study is the fairly low num-
ber of sputums due to the fact that Liège is the only
center to use sputum in routine checkup. This could be
skewing the data in favor of neutrophilic phenotype for
low BEC group, although it is well established that low
BEC can have high sputum eosinophils.
In our study, in a small population of patients with
eosinophilia despite OCS treatment, we found
normalization of BEC under anti-IL5 therapy. With anti-
IL5 therapy, a reduction in blood eosinophils is achieved,
even in those patients who presented persistent eosino-
philia under OCS therapy [36]. More importantly, the
introduction of an anti-IL5 treatment allowed an oppor-
tunity to reduce the OCS dose in these patients.
Surprisingly, in a fairly small number of patients of this
cohort of severe asthmatics, highly uncontrolled asthma
was not associated with a high BEC as we could have ex-
pected. Instead, it was characterized by impaired lung
function (low FEV1) and diffusion capacity, and higher
rate of emphysema (52%). Emphysema which is associated
with lower diffusion capacity, may be a cause of dyspnea,
which is a symptom considered in the evaluation of
asthma control. These subjects fulfill the profile of patients
with Asthma COPD overlap. In contrast, as previously re-
ported [25], some patients with a late-onset eosinophilic
phenotype present with low symptom expression despite
high inflammation. These are poor perceivers with overes-
timated asthma control, but are at risk for exacerbations.
Conclusion
Approximately one-fifth of SA patients were treated with
maintenance OCS at enrollment in BSAR. We demon-
strated a significant association between late-onset, exac-
erbations, non-atopic status and chronic use of OCS in
this population. Almost half of SA patients treated with
chronic OCS have BEC ≥400/mm3. Moreover, we show
a significant association between high BEC and late-
onset asthma in OCS maintenance SA patients.
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